Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 25, 2007 Brian Orelli	Cold HIV Vaccine Gets Frozen Phase 2 clinical trials of Merck's HIV vaccine were frozen, leaving the door open for other drugmakers that have vaccines of their own in early trials. Investors, take note.
Pharmaceutical Executive December 1, 2005 Alana Klein	Thought Leader: A Q&A with Graham Allaway While researchers continue to hunt for new AIDS drugs, Graham Allaway, chief operating officer of Panacos Pharmaceuticals, is focusing on developing a treatment for patients failing therapy due to resistance.
Fast Company August 8, 2011 Kate Rockwood	AIDS Vaccine Conference Despite billions in annual research dollars, the quest for an AIDS vaccine remains elusive.
The Motley Fool September 24, 2009 Brian Orelli	Drugmakers' HIV Treatments Live On Companies that make HIV drugs could lose billions of dollars in revenue if an effective vaccine is developed. All drug-company investors need to keep an eye on up-and-coming drugs from competitors that could take market share.
The Motley Fool February 27, 2007 Brian Lawler	Gilead's Green-Lighted Drug Having a diversified drug pipeline is what makes large-cap drug stocks like Gilead so enticing, even to risk-adverse investors.
The Motley Fool October 16, 2007 Brian Orelli	Not a Blockbuster -- Yet Merck gains marketing approval for its newest HIV drug. Investors, take note.
Chemistry World September 26, 2007 Victoria Gill	HIV Vaccines 'Will Not Work' Just days after US drug firm Merck revealed its leading HIV vaccine candidate had flopped in clinical trials, a leading immunologist has predicted that many other vaccines in the pipeline will also fail because their design is similarly flawed.
Chemistry World February 9, 2007 Victoria Gill	Africa's First Large-Scale HIV Vaccine Trial The first large-scale clinical trial of an HIV vaccine will involve around 3000 participants in five selected sites in South Africa. It will compare the effectiveness of the vaccine at reducing HIV infection compared to a placebo.
The Motley Fool January 21, 2010 Brian Orelli	Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really?
Chemistry World September 3, 2009 Sarah Houlton	New HIV vaccine hope A team of scientists in the US has discovered two new antibodies that could lead to an HIV vaccine.
BusinessWeek April 1, 2010 Bennett & Randall	Will an AIDS Pill a Day Keep the Virus Away? Drugmaker Gilead is betting the one-pill PrEP treatment will slow the virus' spread - as are some of the world's top health agencies and philanthropists.
Chemistry World July 11, 2012	Gsk Drug Shines in HIV Trial GlaxoSmithKline has announced good results for its HIV - Aids drug candidate dolutegravir, which has apparently outperformed Atripla tablets in Phase III.
The Motley Fool September 7, 2007 Brian Orelli	Merck Says No to This Protein An FDA advisory panel recommends unanimous approval of a new HIV drug from Merck. The new class of HIV medications fight the virus by blocking one key protein from entering cells.
BusinessWeek October 20, 2003 Gene G. Marcial	How Immune Response Targets AIDS Immune Response's Remune is aimed at slowing the advance of HIV and delaying the need for antiretroviral drugs, which have toxic effects. A look at the company's situation and its stock.
AskMen.com	Vaccine Helps Prevent HIV For the first time, an experimental vaccine has prevented infection with the AIDS virus, a watershed event in the deadly epidemic and a surprising result.
BusinessWeek September 12, 2005 John Carey	A Better Way To Ambush AIDS? HIV increasingly outwits today's drugs even as side effects take a toll. But Panacos Pharmaceuticals' experimental drug opens the door to a new line of attack.
Pharmaceutical Executive July 30, 2007 Walter Armstrong	Tibotec Gets AIDS With a new wave of "resistant to resistance" HIV drugs, a record of consistent innovation, and a dynamic partnership with AIDS activists, Tibotec is in it to win it. And end it.
The Motley Fool December 31, 2007 Brian Lawler	Best Stock for 2008: Gilead Sciences Shares of Gilead Sciences are a good bet for next year.
The Motley Fool June 26, 2008 Brian Lawler	Ardea Takes the More Exciting Route Ardea Bioscicences announces phase 2a data for its lead anti-HIV drug that is good enough to encourage further testing.
Popular Mechanics December 1, 2006 Ben Harder	Fighting HIV by Building a New Killer In the fight to find a cure for AIDS, researchers have invented a viral double agent on a mission to seek out where HIV hides.
The Motley Fool June 17, 2010 Luke Timmerman	Oncothyreon's Cancer Vaccine Back in the Saddle as Merck KGaA Re-Starts Clinical Trials The German-based Merck got clearance from the FDA and local ethics review boards to resume two of three large pivotal trials.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA
Wired January 2003 Richard Martin	Testing the First AIDS Vaccine Medical establishment, government, and Genentech be damned -- Don Francis has never stopped believing. Now he's about to finish testing the first human AIDS vaccine.
Chemistry World March 10, 2008 Victoria Gill	New Hope for Anti-HIV Gels Early data from a clinical trial has rekindled hope of an effective topical gel to prevent HIV infection.
Chemistry World September 24, 2015	A new hope in HIV prevention New microbicide products could turn the tide against Aids for those who need it most: women in sub-Saharan Africa. Dinsa Sachan reports.
BusinessWeek September 2, 2010 Simeon Bennett	David Margolis' Fight to End AIDS The North Carolina professor is relying on Zolinza, a rarely used Merck cancer drug, to stamp out AIDS.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	HIV: Better Combos and Classes Keep Coming The new class of integrase inhibitors is the main event on the calendar, as Gilead's elvitegravir and ViiV Healthcare's GSK 1349572 come online in 2013 and 2014, respectively.
Chemistry World October 23, 2014 Rebecca Trager	US agency fast-tracks Ebola vaccine development The US Department of Health and Human Services is fast-tracking tests on an Ebola vaccine by providing $5.8 million under a one-year contract with the Maryland-based biotech company Profectus BioSciences
The Motley Fool November 29, 2010 Brian Orelli	Head to Head: Merck vs. Itself Merck's HIV drug doesn't work as well when taken once daily.
Chemistry World April 27, 2007 Ned Stafford	New HIV Blocker Prepares for Trials Scientists who isolated a natural component of human blood that defends against the HIV-1 virus are now moving quickly to test their ideas clinically in the hope of bringing a new class of HIV-blockers based on peptide therapeutics to market.
Pharmaceutical Executive December 1, 2006	Pipeline 32 compounds that are the early fruit of pharma's investment in targeted drug design.
Pharmaceutical Executive September 1, 2010	Is There a Balm for Gilead? A new leader, a big acquisition, and a bold investment in HIV may all be in the works at Gilead. But what will it take to restore the glory days?
Chemistry World August 20, 2014 Maria Burke	Doctors turn to experimental Ebola treatments The emergency use of an experimental medicine is highly unusual, but the WHO has declared the Ebola outbreak a public health emergency of international concern.
Scientific American October 2008 John Rennie	Hope and the Fight against HIV The battle must continue, even if 25 years of research have disappointed.
The Motley Fool June 25, 2010 Brian Orelli	Diversification Times 50,000 Gilead Sciences diversifies any way it can.
Scientific American November 2008 Jessica Wapner	Cancer Vaccine: Looking Beyond Tumor Size Proponents see hope in changing cancer vaccines' bad reputation
Chemistry World April 17, 2008 Nuala Mora	World's first therapeutic cancer vaccine approved In move that will be a fillip to cancer vaccine developers, US biotech Antigenics has won Russian approval to market Oncophage to treat kidney cancer.
The Motley Fool April 6, 2010 Brian Orelli	Kill It! Double-Teaming Malaria Malaria vaccine might not make Glaxo and Crucell rich, but the life-saving and PR benefits would be welcome.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool July 19, 2007 Brian Orelli	Trimeris Reaches a Plateau Drug developer Trimeris needs to push another drug out of its pipeline because sales of its only drug, Fuzeon, appear to be hitting the wall. Investors, take note.
The Motley Fool October 17, 2008 Brian Orelli	Gilead Sciences Killed It The virus-killer kills analysts' expectations, as well. The company blows through analysts' expectations with its third-quarter results.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
The Motley Fool March 24, 2011 Brian Orelli	It's the Combo That Matters for Gilead The same efficacy with fewer pills is the headline, but it's the understory that makes Gilead Sciences' latest clinical trial success important for investors.
The Motley Fool December 30, 2008 Brian Orelli	A Shot in the Arm for Novartis' Pipeline The company picks up the rights to a vaccine that fights a virus.
The Motley Fool July 19, 2010 Brian Orelli	Abbott Labs Loves Merck More Than Gilead Its HIV trial seems to suggest so.
The Motley Fool May 2, 2007 Brian Lawler	Progenics' Intriguing Study Results The development-stage drugmaker released clinical trial results for one of its compounds. Investors, take note.
The Motley Fool August 24, 2005 Tarek Sultani	Panacos Gives HIV Reason to Panic Panacos' new anti-retroviral PA-457 has huge implications for the company's future. The stock price soared 46% Monday, closing at $10.30. While this surge may seem enormous, it's only the tip of the iceberg if this drug proves as successful as these trials indicate.
The Motley Fool July 13, 2004 Charly Travers	With Pfizer Drug, HIV Retreats Pfizer's newest HIV treatment shows promise in a demanding market.
Pharmaceutical Executive October 1, 2014 Jill Wechsler	Ebola Crisis Challenges Pharma R&D Companies gain support and pressure to deliver new treatments for spreading outbreak.
The Motley Fool October 20, 2010 Brian Orelli	What's Your Next Trick, Gilead? Just when investors had counted Gilead Sciences down for the count, it comes roaring back.